 |
|
Estrogen Replacement Therapy in Breast Cancer Survivors-Reply
Melody A. Cobleigh, MD
Rush-Presbyterian-St Luke's Medical Center Chicago, Ill
Robert F. Berris, MD
Hematology-Oncology Associates Denver, Colo
Trudy Bush, PhD, MHS
The Johns Hopkins School of Hygiene and Public Health
Nancy E. Davidson, MD
The Johns Hopkins Oncology Associates Baltimore, Md
Nicholas J. Robert, MD
Fairfax Oncology Associates Annandale, Va
Joseph A. Sparano, MD
Albert Einstein Cancer Center New York, NY
Douglas C. Tormey, MD, PhD
Eastern Cooperative Oncology Group Operations Office Denver, Colo
William C. Wood, MD
Emory University School of Medicine Atlanta, Ga
JAMA. 1995;273(8):621.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
In Reply.
—We thank the many authors of letters written in response to our work.
Meta-analyses, which overcome type II error, have not demonstrated an association between ERT and risk of breast cancer. In general, prospective studies are preferable to case-control studies. However, there are problems with all studies, including prospective ones.
For example, the Nurses' Health Study found an increase in breast cancer risk only in those who were drinking alcohol.1 The Swedish study wasn't a true prospective cohort trial.2 Files from a prescription database were merged with files from a cancer registry. It is not known whether "hormone users" were actually taking hormones.
We need to weigh the entire body of evidence. We should not discount the results of 25 case-control studies because we think two prospective ones are better.
Most studies of adjuvant tamoxifen in postmenopausal women evaluated tamoxifen vs no treatment, whereas those in
. . . [Full Text PDF of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
